| Business Summary | | Ariad
Pharmaceuticals,
Inc.
develops
pharmaceutical
product
candidates
based
on
small-molecule
drugs
and
its
proprietary
gene
regulation
technology
platforms.
The
Company
integrates
functional
genomics
and
proteomics,
protein
engineering,
and
structure-based
drug
design
in
its
drug
discovery
process.
All
of
the
Company's
product
candidates
work
through
small-molecule
regulation
of
cellular
processes.
Ariad
currently
has
four
development
programs:
a
dual-action
drug
candidate
for
osteoporosis
that
both
blocks
bone
resorption
and
stimulates
bone
formation;
a
drug
candidate
for
cancer
that
blocks
cell
proliferation
and
tumor
growth;
a
regulated
cell
therapy
product
candidate
for
graft-versus-host
disease
(GvHD)
that
selectively
eliminates
donor
T-cells
following
allogeneic
bone
marrow
transplantation
(BMT),
if
they
attack
the
patient's
own
tissues;
and
a
protein
therapy
for
anemia
that
provides
precisely
controlled
erythropoietin
production
in
vivo
using
an
orally
administered
drug. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Ariad
Pharmaceuticals
is
focused
on
the
discovery
and
development
of
novel
and
proprietary
drugs
based
on
its
understanding
of
the
inner-workings
of
cells
and
the
genes
involved
in
disease.
For
the
six
months
ended
6/30/01,
revenues
rose
6%
to
$935
thousand.
Net
loss
rose
32%
to
$8.9
million.
Revenues
reflect
higher
interest
income
due
to
higher
invested
cash
balances.
Higher
loss
reflects
higher
product
development
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Harvey Berger, M.D., 50 Chairman,
Pres and CEO | $366K | $432K | Sanford Smith, 53 Vice
Chairman | -- | -- | Lee Steele, 51 CFO,
Sr. VP, Treasurer | -- | -- | David Berstein, 48 Sr.
VP and Chief Patent Counsel | 203K | 1.5M | Fritz Casselman, 51 Sr.
VP and CBO | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|